Insulet (NASDAQ:PODD) Price Target Raised to $158.00

Insulet (NASDAQ:PODD) had its price target upped by Raymond James from $135.00 to $158.00 in a research note released on Wednesday, AnalystRatings.com reports. Raymond James currently has an outperform rating on the medical instruments supplier’s stock.

A number of other equities analysts also recently weighed in on the stock. UBS Group downgraded shares of Insulet from a buy rating to a neutral rating and increased their price target for the stock from $155.00 to $160.00 in a research note on Friday, October 4th. They noted that the move was a valuation call. Morgan Stanley increased their price target on shares of Insulet from $127.00 to $135.00 and gave the stock an equal weight rating in a research note on Tuesday, August 6th. JPMorgan Chase & Co. raised shares of Insulet from a neutral rating to an overweight rating and increased their price target for the stock from $120.00 to $155.00 in a research note on Tuesday, August 6th. Stifel Nicolaus started coverage on shares of Insulet in a research note on Tuesday, October 22nd. They set a hold rating and a $163.00 price target on the stock. Finally, ValuEngine downgraded shares of Insulet from a buy rating to a hold rating in a research note on Wednesday, October 2nd. Ten analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $151.71.

NASDAQ:PODD opened at $169.46 on Wednesday. The company has a quick ratio of 3.91, a current ratio of 4.72 and a debt-to-equity ratio of 2.43. The company has a market cap of $8.73 billion, a P/E ratio of 3,389.20 and a beta of 0.96. Insulet has a fifty-two week low of $70.80 and a fifty-two week high of $171.96. The firm’s 50 day moving average is $154.75 and its two-hundred day moving average is $130.77.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.03 by ($0.02). The company had revenue of $192.12 million for the quarter, compared to analysts’ expectations of $179.50 million. Insulet had a return on equity of 9.46% and a net margin of 2.38%. The business’s revenue for the quarter was up 27.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.03 EPS. Research analysts forecast that Insulet will post 0.23 earnings per share for the current fiscal year.

In related news, SVP Michael P. Spears sold 4,153 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.12, for a total transaction of $606,836.36. Following the completion of the sale, the senior vice president now directly owns 22,626 shares of the company’s stock, valued at approximately $3,306,111.12. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Shacey Petrovic sold 689 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $145.69, for a total transaction of $100,380.41. Following the sale, the chief executive officer now directly owns 94,510 shares of the company’s stock, valued at $13,769,161.90. The disclosure for this sale can be found here. In the last three months, insiders sold 5,491 shares of company stock worth $806,124. Insiders own 3.50% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC grew its holdings in Insulet by 4.9% during the 2nd quarter. Janus Henderson Group PLC now owns 369,611 shares of the medical instruments supplier’s stock valued at $44,124,000 after purchasing an additional 17,328 shares in the last quarter. Swiss National Bank grew its holdings in Insulet by 2.4% during the 2nd quarter. Swiss National Bank now owns 110,300 shares of the medical instruments supplier’s stock worth $13,168,000 after acquiring an additional 2,600 shares in the last quarter. Jennison Associates LLC grew its holdings in Insulet by 53.6% during the 2nd quarter. Jennison Associates LLC now owns 283,817 shares of the medical instruments supplier’s stock worth $33,882,000 after acquiring an additional 98,995 shares in the last quarter. Columbus Circle Investors grew its holdings in Insulet by 74.6% during the 2nd quarter. Columbus Circle Investors now owns 165,863 shares of the medical instruments supplier’s stock worth $19,801,000 after acquiring an additional 70,860 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Insulet by 2.7% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 365,617 shares of the medical instruments supplier’s stock worth $43,648,000 after acquiring an additional 9,446 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Recommended Story: Understanding the Price to Earnings Ratio (PE)

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.